摘要:
The invention provides an attenuated polio virus having a 5′ non-coding region consisting of the 5′ non-coding region of Sabin 3, modified so that it does not have a base pair mismatch in stem (a) or (b) of domain V, wherein seven or eight of the base pairs in stems (a) and (b) are U-A or A-U base pairs; and a capsid protein from the Sabin 1, Mahoney, MEF or Saukett strain.
摘要:
The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.
摘要:
The present invention relates to methods for producing RNA virus cDNA, methods for producing viable, RNA virus and viable, RNA virus produced by those methods. The invention also related to a novel RNA virus cDNA, recombinant DNA molecules containing that cDNA and hosts transformed with those recombinant cDNA molecules. This invention further related to novel methods for screening for variants of a strain 3 poliovirus. This invention also related to methods for increasing the attenuation of a strain poliovirus.This invention provides a vaccine useful for immunizing a subject, for example a human, against infectious poliovirus, wherein the vaccine comprises an effective amount of an RNA virus, produced by transforming a suitable host cell with a recombinant nucleic acid sequence which encodes for the virus: culturing the host cell under conditions which permit the production of virus: and isolating the virus so produced, effective to immunize the subject, and a suitable carrier. Further provided to this invention is a method of immunizing a subject such as a human against infectious poliovirus, wherein the method comprises administering the subject a suitable dose of the vaccine described hereinabove.
摘要:
The molecular cloning and characterization of a novel human immunodeficiency virus type 2 (HIV-2), designated HIV-2.sub.ROD, is described. A recombinant .lambda. phage genomic library was screened with an HIV-2-specific probe to identify overlapping subgenomic clones. Fragments of these .lambda. phage clones were subcloned into a suitable vector to reconstitute the complete HIV-2.sub.ROD genome. The complete nucleotide sequence of this proviral clone was ascertained and the following genes and gene products identified: gag (including p16, p26, and p12), pol, vif, vpr, vpx, env, tat, rev, and nef. These gene products will be useful, inter alia, in in vitro diagnostic methods and kits for the detection of HIV-2-specific antisera.
摘要:
This invention relates to a recombinant plasmid comprising the cyaC and the cyaA genes of Bordetella which directs the expression of Bordetella adenylate cyclase in a transformed host cell. This invention also relates to a recombinat DNA molecule comprising the Bordetella cyaA gene containing at least one insertion of a heterologous DNA sequence at at least one permissive site. This invention further relates to recombinant Bordetella adenylate cyclase comprising a heterologous epitope at a permissive site as well as methods of inducing a specific B cell, helper T cell, and CTL cell immune response.
摘要:
An attenuated poliovirus in which the 5' non-coding region of the genome is:(a) the 5' non-coding region of poliovirus type 3 Leon strain modified by the provision of the bases uracil and adenine at positions 472 and 537 thereof respectively, or(b) the 5' non-coding region of another poliovirus modified by the provision of the bases uracil and adenine at respective positions corresponding to position 472 and 537 of the 5' non-coding region of poliovirus type 3 Leon strain.
摘要:
A recombinant plasmid comprises the cyaC and the cyaA genes of Bordetella which directs the expression of Bordetella, adenylate cyclase in a transformed host cell. A recombinant DNA molecule can comprise the Bordetella cyaA gene containing at least one insertion of a heterologous DNA sequence at at least one permissive site. In addition, a recombinant Bordetella adenylate cyclase comprises a heterologous epitope at a permissive site. Methods of inducing a specific B cell, helper T cell, and CTL cell immune response are provided.
摘要:
Methods, pharmaceutical compositions and vaccines comprising an attenuated bacteria that expresses a recall antigen are disclosed for treatment of cancer.
摘要:
The present invention pertains to a method of encapsidating a recombinant poliovirus nucleic acid to obtain a yield of encapsidated viruses which substantially comprises encapsidated recombinant poliovirus nucleic acid. The method of encapsidating a recombinant poliovirus nucleic acid includes contacting a host cell with a recombinant poliovirus nucleic acid which lacks the nucleotide sequence encoding at least a portion of a protein necessary for encapsidation and an expression vector comprising a nucleic acid which encodes at least a portion of one protein necessary for encapsidation under conditions appropriate for introduction of the recombinant poliovirus nucleic acid and the expression vector into the host cell and obtaining a yield of encapsidated viruses which substantially comprises an encapsidated recombinant poliovirus nucleic acid. A foreign nucleotide sequence is generally substituted for the nucleotide sequence of the poliovirus nucleic acid encoding at least a portion of a protein necessary for encapsidation. The invention further pertains to encapsidated recombinant poliovirus nucleic acids produced by the method of this invention and compositions containing the encapsidated or nonencapsidated recombinant poliovirus nucleic acid containing a foreign nucleotide sequence for use in a method of stimulating an immune response in a subject to the protein encoded by the foreign nucleotide sequence.
摘要:
Replication-competent recombinant viruses, particularly replication-competent recombinant polioviruses, which include (1) exogenous nucleic acid sequences which encode an exogenous polypeptide and (2) a nucleic acid sequence which encodes an artificial proteolytic cleavage site for a viral or cellular protease which proteolytically processes (cleaves) the precursor protein produced by the parent virus and uses therefor. The recombinant precursor is cleaved into the usual array of constituent proteins, freeing the exogenous polypeptide. Replication-competent recombinant viruses are useful as vaccines against bacterial, viral, fungal and yeast infections, parasitic diseases, cancer and allergies.